Healthcare Professionals

This content is intended for healthcare professionals only, for informational and scientific purposes.

I am a healthcare professional and I have read and understood the information above.

Patients or General Public

This content is intended for healthcare professionals.

I am a patient or a member of the general public and I have read and understood the information above.

Continue as a Patient or general public

“Real-world use of encorafenib + cetuximab with BRAFV600E-mutant metastatic colorectal cancer:
European pooled study1”

Discover the poster presented at ESMO Gastrointestinal Cancers Congress 2025 and the exclusive interview with the last author of the study, Prof. Sebastian Stintzing

Download the poster

Largest real-world cohort with BRAFV600E-mutant metastatic colorectal cancer (mCRC) treated with encorafenib + cetuximab after prior systemic therapy1

A population of 709 patients, with BRAFV600E-mutant metastatic colorectal cancer, pooled from five European real-world studies conducted between 2020 and 2024 was analyzed. Clinical and patient characteristics, treatment patterns and sequencing, BRAF testing and the effectiveness and safety of encorafenib + cetuximab after prior systemic therapy were evaluated1.

Download the poster

Prof. Sebastian Stintzing, as the author, provides context for these findings

Pr Sebastien Stintzing

Head of the Department of Hematology, Oncology, and Tumor Immunology (CCM) of Charité Universitaetsmedizin Berlin (Germany)

Contact us

REICHENBACH Franck

Medical Advisor Oncology

Contact Franck
1. Cremolini C, et al. Annals of Oncology. 2025;36 (S23-S24): abstract 38P (poster presentation at ESMO GI 2025)